1. Derek D. Poore
107 Crestwood Court | Douglassville, PA 19518 | 717-449-9520 | pooreder@hotmail.com
Summary
Accomplished and highly talented scientist with extensive experience in molecular and cellular biology and early drug discovery.
Keen understanding of cellular models, various screening platforms and assay technologies. Dedicated team player committed
to managing projects impeccably while contributing to team programs and company goals. Effective communicator who easily
interfaces and collaborates with colleagues and external collaborators. A versatile and dependable professional who can adapt
to new technologies and disciplines.
Areas of Expertise
 Cellular and biochemical medium and high throughput
compound screening
 Cellular and biochemical mechanism of action assays
 Phenotypic cellular assay compound screening
 Cellular assay formats (MSD, LanthaScreen, TR-FRET,
HTRF, ELISA, reporter, proliferation and ALPHALISA)
 Biochemical assay formats (TR-FRET, HTRF, FP, and
FLINT, DELFIA)
 Cell culture (primary cells such as PBMCs, stable,
transfected and transduced cell lines)
 Receptor radioligand binding assays
 GPCR functional screening assays (EIA, SPA and
FlashPlate)
 Parallel Artificial Membrane Permeability Assay (PAMPA)
compound screens
 Western blot analysis
 Protein expression and purification
 HPLC compound separation
 Molecular techniques (gel electrophoresis, PCR, DNA
isolation, cloning and sequencing)
 Automated liquid handling systems (Echo, Bravo, Quadra
96 and Biomek 2000/FX)
 Plate readers (MSD, Pherastar, Envision and ViewLux)
 Upload data to internal databases and maintain relevant
internal databases (Abase and KATE)
 Computer skills: MS Excel, MS Power Point, MS Word,
MS Access, Windows, Spotifre, Prism GraphPad,
SigmaPlot, OR&M, Helium and literature search
(PubMed)
Professional and Academic Honors
 GSK Silver R&D Recognition Award for contributions to immuno-oncology program in development of human PBMC assays
that enabled candidate selection of the program, 2014.
 GSK Bronze R&D Recognition Award for development cellular functional assays in human PBMC’s support to Sirt1
program, 2014.
 GSK Silver R&D Recognition Award for championing key ideas, innovative and creative experimentation on developing key
cellular assays for biosynthetic chemistry project, 2012.
 GSK Silver R&D Recognition Award for development of high throughput cellular mechanistic assay that demonstrated
compound cell permeability and potent inhibitors for immuno-inflammation program, 2011.
 GSK Exceptional Science Award for outstanding and instrumental contributions to generation of Nrf-Keap1 and Cul3-Keap1
TR-FRET, two key assay which helped establish Nrf2 program, 2010.
 GSK Bronze R&D Recognition Award for development and implication of key biochemical assays (FP & TR-FRET) for hit
triage and MOA studies of Nrf2-Keap1 interactions, 2010.
 GSK Bronze R&D Recognition Award for contributing to DELFIA cellular assay development for cardiac heart failure
program, 2009.
 GSK Bronze R&D Recognition Award for development of robust 1536 cellular based assay for NOD1 program, 2009.
 GSK Bronze R&D Recognition Award for efforts in development of LDHA cellular assay, 2009.
 GSK Bronze R&D Recognition Award for significant impact on kinase program by developing a sensitive and robust DNA-
PK LanthaScreen assay, 2008.

2.  Virginia Military Institute Post-Graduate Education Scholarship, Virginia Military Institute, 2001
 Young Scientist Travel Fellows, 27th Meeting of the Federation of European Biochemical Societies, 2001
 Tharp Travel Award (given to outstanding graduate student presenting at a meeting), University of South Florida, 2001
 American Society for Biochemistry and Molecular Biology Graduate/Postdoctoral Travel Award
ASBMB/ASPET Joint Meeting, 2000
 Tharp Travel Award (given to outstanding graduate student presenting at a meeting),University of South Florida, 2000
Professional Experience
GlaxoSmithKline
Collegeville, PA
Senior Scientist
2010-Present
 Provided assay and screening strategies for a phosphatase program, including developing multiple cellular based assays
and MOA studies
 Instrumental in establishing high throughput cellular assays in measuring cytokines in primary cells such as PBMCs which
helped drive various programs and solve critical questions about compounds
 Provided scientific input and strategic guidance to phosphatase and immuno-inflammation programs which guided
programs’ chemistry efforts
 Lead and directed corroborations efforts with analytical chemistry group on cellular based Rapidfire assay for immuno-
oncology program
 Trained colleagues on isolation of immune cells from whole blood and developing cell based flow cytometry assay for
immuno-oncology program
 Supervised a co-op worker in cell culture techniques and cellular based assay development
 Elected as a PTS reviewer for GSK Discovery Fast Track academia proposals
 Development of disease-relevant cell based assay for immuno-oncology program that enabled candidate selection of the
program
 Instrumental in the development of a vitamin D sensor cell based assay that guided the efforts of a biosynthetic chemistry
project
 Championed Keap1 high throughput mutagenesis project for respiratory stress repair program which established new
molecular biology and purification techniques in for high throughput mutagenesis
 Supported and developed array of Nrf2 biochemical assays (TR-FRET & FP) that were instrumental in the selection of
candidate molecules of Nrf2 program for stress and repair DPU in respiratory therapeutic area
 Evaluation and development of a cell based GFP LanthaScreen assay using customized neoepitope antibody for DELFIA
assay which established compound permeability and cellular potency
Scientist
2007-2009
 Instrumental in setting up human PBMC screening assays in the department for hit identification
 Developed a sensitive DNA-dependent protein kinase (DNA-PK) Lanthascreen assay that provided timely and critical
compound data for kinase program
 Successfully developed a high throughput cellular luciferase gene reporter assay for cardiovascular program
 Instrumental in evaluating and implementing new assay technologies such as AlphaLISA and Lanthascreen in the
department
 Developed immuno-inflammatory cellular assay for the detection of the inhibition of NOD1 protein by measuring IL8 levels
 Developed oncology cellular assay for the detection of the inhibition of LDHA enzyme by measuring pyruvate levels through
enzymatic coupling assay that was critical for supporting hit triage following biochemical HTS
Palatin Technologies
Cranbury, NJ
Associate Scientist
2006-2007
 Developed assays to characterize drug-receptor interactions and mechanism of action that key for compound progression
 Developed MAP Kinase western blot analysis to screen obesity lead compounds for MAP Kinase activity
 Developed radioligand binding assays for atrial natriuretic peptide receptors

3.  Characterized species selectivity of lead compounds by developing cellular functional assays for cardiac heart failure program.
 Quantified cGMP levels in animal plasma for cardiac heart failure program
 Presented data at weekly group meetings and journal club meetings
Senior Research Associate
2004-2006
 Melanocortin receptor drug screening and assay development for obesity, cachexia and sexual dysfunction programs through
radioligand binding assays
 Melanocortin receptor drug screening and assay development for obesity, cachexia and sexual dysfunction programs through
receptor cellular functional assays (HTRF, ELISA and Flash Plates)
 Developed, validated and performed radioligand binding assays to screen compounds against dopamine receptors
 Developed PAMPA assay to determine permeability of obesity lead compounds through various phospholipid layers
 Looked at displacement of 125I NDP-MSH against obesity compounds in rat brain through autoradiography
 Maintain obesity melanocortin compound functional screening database that included data from both low and high receptor density
levels
 Presentation of data at weekly group meetings
Research Associate
2002-2004
 Developed, validated and performed radioligand binding assays to screen compounds against melanocortin, bombesin and
calcitonin gene-related peptide receptors
 Quantified Bremelanotide (erectile dysfunction drug) levels in animal plasma through RIA and SPA for erectile dysfunction program
 Presented data at weekly group meetings
University of South Florida Department of Chemistry
Tampa, FL
Research Assistant
1999 – 2002
 Purified enzyme, acyl-CoA:glycine N-acyltransferase from bovine liver
 Cloned, expressed and purified recombinant enzyme, acyl-CoA:glycine N-acyltransferase
 Developed reversed phase HP liquid chromatography to monitor conversion of N-fatty acylglycines to primary fatty acid
amides by peptidylglycine-alpha-amidating monooxygenase
Teaching Assistant
1999 - 2002
 Taught Basic Biochemistry lab, Organic Chemistry I, General Chemistry I and II labs to undergraduate college students
Duquesne University Department of Chemistry
Pittsburgh, PA*
Research Assistant
1998 - 1999
*Left graduate program at Duquesne University when mentor took a faculty position at USF
 Developed reversed phase HP liquid chromatography separation protocols for the separation of N-fatty acylglycines and
primary fatty acid amides
 Learned various molecular biology techniques when studying the mechanism of transposons
Teaching Assistant
1998 - 1999
 Taught Organic Chemistry I and II labs to undergraduate college students.
Virginia Military Institute Department of Chemistry
Lexington, VA

4. Undergraduate Research Intern
Summer 1997
 In vitro and in vivo chemo-attraction of cell populations in response to different chemo tactic agents imbedded in an alginate
matrix implanted into bone wound sites
University of North Texas Health Science Center
Fort Worth, TX
Undergraduate Research Intern
Summer 1997
 Examined the role of fetuin in retinal development
Academic Qualifications
Master of Science
July 2002
University of South Florida, Tampa, FL
Concentration: Biochemistry
Bachelor of Science
May 1998
Virginia Military Institute, Lexington, VA
Concentration: Biology with chemistry minor
Oral Presentations
Derek D. Poore. Cellular HTRF Based High Throughput Screening: Parameters To Identify Quality Hits. Oral presentation at 6th
Cisbio HTRF Symposium, Brewster, MA, September 14-17, 2015.
Publications
1. Rickard DJ, Sehon CA, Kasparcova V, Kallal LA, Haile PA, Zeng X, Montoute MN, Poore DD, Li H, Wu Z, Eidam PM,
Emery JG, Marquis RW, Gough PJ, Bertin J. (2014) Identification of selective small molecule inhibitors of the
nucleotide-binding oligomerization domain 1 (NOD1) signaling pathway. PLoS One. May 7;9(5).
2. Rickard DJ, Sehon CA, Kasparcova V, Kallal LA, Zeng X, Montoute MN, Chordia T, Poore DD, Li H, Wu Z, Eidam PM,
Haile PA, Yu J, Emery JG, Marquis RW, Gough PJ, Bertin J. (2013) Identification of benzimidazole diamides as
selective inhibitors of the nucleotide-binding oligomerization domain 2 (NOD2) signaling pathway. PLoS One. Aug
1;8(8).
3. Carpenter T, Poore DD, Gee AJ, Deshpande P, Merkler DJ and Johnson ME. (2004) Use of reversed phase HP liquid
chromatography to assay conversion of N-acylglycines to primary fatty acid amides by peptidylglycine-alpha-amidating
monooxygenase. J Chromatogr B Analyt Technol Biomed Life Sci. 809(1): 15-21.
4. Miller LA, Baumgart LE, Chew GH, deLong MA, Galloway LC, Jung KW, Merkler KA, Nagle AS, Poore DD, Yoon CH,
Merkler DJ. (2003) Glutathione, S-substituted glutathiones, and leukotriene C4 as substrates for peptidylglycine alpha-
amidating monooxygenase. Arch Biochem Biophys. 412(1): 3-12.
5. Poore, D.D., Merkler, K.A. and Merkler, D.J. (2001) Cloning, expression and purification of bovine liver acyl-coa:
glycine N-acyltransferase in E. coli strain BL21(DE)pLysS. European Journal of Biochemistry. 268 (1),166.
6. Poore, D.D., Aycock, H., Gee, A.J., Johnson, M.E. and Merkler, D.J. (2000) Reverse-phase HPLC separations on N-
acylglycines & acylamides. FASEB Journal. 14 (8), 618.
Poster Presentations
1. Hongwei Qi, Derek D. Poore , Wangfang Hou, Thomas D. Sweitzer, Sharon Sweitzer, Robert S. Ames and Hu Li.
Expression, Purification and Validation of Keap1 protein using Keap1/Nrf2 TR-FRET Assay. Poster pesented to Society of
Biomolecular Sciences 14th Annual Conference & Exhibition, Orlando, FL, March 27-31, 2011.

5. 2. Derek D. Poore, Hongwei W. Qi, Matthew V. Will, Wangfang Hou, Thau Ho, Robert S. Ames and Hu Li. Development of
Keap1/Nrf2 and Keap1/Cul3 TR-FRET assays. Poster pesented to Society of Biomolecular Sciences 14th Annual
Conference & Exhibition, St. Louis, MO, April 7-11, 2008.
3. J. Michael Padron, R.J. Setters, G.W. Herbert, A.A. Hause, Y. Shi, P. Purma, Z. Wu, B. Hu, R. Rajpurohit, Shobha E.
Senadhi, D. Poore, U. Mirshahi, A.M. Shadiack, S.D. Sharma, and K.D. Burris, Novel small Melanocortin-4-Receptor
Agonist decreases feeding and body weight without aversive effects, illness or erectile activity. Poster presented to North
American Society for the Study of Obesity (NAASO) Meeting, Las Vegas, NV, November 14-18,2004.
4. Robert Setters, J. Michael Padron, Yi-Qun Shi, Papireddy Purma Zhijun Wu, Annette M. Shadiack, Ramesh Rajpurohit,
Shobha Senadhi, Derek Poore, Uyenlinh Mirshahi, Shubh D. Sharma and Kevin D. Burris. Regulation of food intake by
MCR4 agonists. Poster presented to Neuroendocrinology of Energy Balance and Obesity Seminar, Washington, D.C, 2004.
5. Poore, D.D., Merkler, K.A. and Merkler, D.J. (2001) Cloning, expression and purification of bovine liver acyl-coa: glycine N-
acyltransferase in E. coli strain BL21(DE)pLysS. Poster presented to 27th Meeting of the Federation of European
Biochemical Societies, Lisbon, Portugal, June 30-July 5, 2001.
6. Poore, D.D., Aycock, H., Gee, A.J., Johnson, M.E. and Merkler, D.J. Reverse-Phase HPLC Separations on N-Acylglycines
& Acylamides. Poster presented to American Society for Biochemistry and Molecular Biology/ASPET 2000 Meeting, Boston,
MA, June 4-8, 2000.
7. Poore, D.D., Aycock, H., Gee, A.J., Johnson, M.E. and Merkler, D.J. RP-HPLC Separations of Peptidylglycine Alpha-
Amidating Monooxygenase Substrates. Poster presented to Florida Annual Meeting and Exposition, Florida Section
American Chemical Society, Orlando, FL, May 12-13, 2000.
8. Poore, D.D., Gee, A.J., Johnson, M.E., and Merkler, D.J. HPLC Separations of Fatty Acids, N-Acylglycines and Acylamides.
Poster presented to 31ST Central Regional Meeting of the American Chemical Society, Columbus, OH, June 21-23, 1999.
Scientific Meetings Attended
 American Association for Cancer Research 102nd Annual Meeting, Orlando, FL, April 2-6, 2011.
 Life Science Regional Technology Symposium, Iselin, NJ, September 15-16, 2009.
 Society for Biomolecular Sciences Cell-Based Assays: Innovations in Reagents,Technologies, and Screening Symposium,
King of Prussia, PA, October 22-24, 2008.
 Geisinger G Protein Coupled Receptor Signaling: Bench to Bedside Meeting, Danville, PA, September 21, 2007.